Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Adult Lymphomas

11 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCPED1537

04/28/2016

T2014-001 A Phase I Trial of Temsirolimus (CC-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Treatment

VICCPHI1531

03/01/2016

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

Treatment

VICCHEM14125

11/13/2015

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Treatment

VICCHEMP1558

10/09/2015

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

VICCPHI14126

09/03/2015

An OpenLabel Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX803 as a Single Agent and in Combination With Carboplatin in Subjects With Advanced Solid Tumors or Lymphoma.

Treatment

VICCBMT1406

06/29/2015

A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies

Treatment

COGAALL1231

05/13/2015

A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Treatment

VICCHEM1490

04/07/2015

Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma and MyD88 L265P Mutation

Treatment

VICCHEM1402

09/15/2014

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Treatment

VICCHEM13105

04/09/2014

A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

Treatment

VICCHEM1146

08/14/2012

Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lyjmphoma